Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975-2022 with insights on the impact of COVID-19
- PMID: 39821472
- DOI: 10.1007/s10147-025-02695-4
Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975-2022 with insights on the impact of COVID-19
Abstract
In Japan, high-quality cancer statistics are collected through cancer registries. However, these data are rarely summarized or reported in research articles. We compiled statistical data on lung cancer in Japan including the COVID-19 pandemic. In 2019, the number of cases of lung cancer in Japan was 126,548. The age-adjusted incidence rate of lung cancer increased from 23.2/100,000 to 42.4/100,000 in males and from 7.2/100,000 to 18.3/100,000 in females between 1975 and 2019. The age-adjusted mortality rate of lung cancer in Japan increased since 2000, after which it decreased. This trend was similar in both males and females. We also investigated statistics on lung cancer worldwide (Australia, Sweden, England, and the United States [USA]). The age-adjusted incidence rate of lung cancer in the data standardized to the world population for males has increased only in Japan; for females, it has decreased only in the USA. Global age-adjusted lung cancer mortality rates have been declining in all countries. In addition, the COVID-19 pandemic has not affected the age-adjusted mortality rate of lung cancer. On the other hand, the number of individuals undergoing lung cancer screening in Japan decreased from 7.92 million in 2019 to 6.59 million in 2020. The COVID-19 pandemic may have affected individuals undergoing lung cancer screening, and its impact on lung cancer needs to be continuously monitored in the future.
Keywords: COVID-19; Epidemiology; International; Japan; Lung cancer; Smoking.
© 2025. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Conflict of interest statement
Declarations. Conflict of interest: Dr. Yamamoto has nothing to disclose. Dr. Shirasawa reports personal fees from MSD, personal fees from Asahi Kasei, personal fees from AstraZeneca.K.K, personal fees from Ono, personal fees from BMS, personal fees from Chugai, personal fees from Eli Lilly, personal fees from Daiichi Sankyo, outside the submitted work; . Dr. Naoki reports personal fees from AstraZeneca.K.K, personal fees from BMS, grants and personal fees from Chugai, grants and personal fees from Nippon Boehringer Ingelheim, grants from ONO, grants from Taiho , grants from PAREXEL, outside the submitted work; .
Similar articles
-
Trends in Lung Cancer Incidence Rates by Histological Type in 1975-2008: A Population-Based Study in Osaka, Japan.J Epidemiol. 2016 Nov 5;26(11):579-586. doi: 10.2188/jea.JE20150257. Epub 2016 Apr 30. J Epidemiol. 2016. PMID: 27150013 Free PMC article.
-
Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic.Cancer. 2025 May 1;131(9):e35833. doi: 10.1002/cncr.35833. Cancer. 2025. PMID: 40257373 Free PMC article.
-
Lung cancer incidence, 2019-2020, United States: The potential impact of the COVID-19 pandemic.Ann Epidemiol. 2024 Oct;98:44-50. doi: 10.1016/j.annepidem.2024.08.005. Epub 2024 Aug 26. Ann Epidemiol. 2024. PMID: 39197807 Free PMC article.
-
[Trends of lung cancer incidence and its prognosis in Osaka, Japan].Gan To Kagaku Ryoho. 1994 May;21(6):727-35. Gan To Kagaku Ryoho. 1994. PMID: 8185326 Review. Japanese.
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
Cited by
-
Lung Cancer incidence in both sexes across global areas: data from 1978 to 2017 and predictions up to 2035.BMC Pulm Med. 2025 Jun 4;25(1):281. doi: 10.1186/s12890-025-03748-0. BMC Pulm Med. 2025. PMID: 40468326 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Horinouchi H, Kusumoto M, Yatabe Y et al (2022) Lung cancer in Japan. J Thorac Oncol 17(3):353–361. https://doi.org/10.1016/j.jtho.2021.11.020 - DOI - PubMed
-
- Sobue T (2000) A case-control study for evaluating lung cancer screening in Japan. Cancer 89(11 Suppl):2392–2396. https://doi.org/10.1002/1097-0142(20001201)89:11+%3c2392::aid-cncr13%3e3... - DOI - PubMed
-
- Punekar SR, Shum E, Grello CM et al (2022) Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol 12:877594. https://doi.org/10.3389/fonc.2022.877594 - DOI - PubMed - PMC
-
- Chirieac LR, Dacic S (2010) Targeted therapies in lung cancer. Surg Pathol Clin 3(1):71–82. https://doi.org/10.1016/j.path.2010.04.001 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical